Hot spots of integrase genotypic changes leading to HIV-2 resistance to raltegravir.
Author(s): Charpentier C, Roquebert B, Delelis O, Larrouy L, Matheron S, Tubiana R, Karmochkine M, Duval X, Chene G, Storto A, Collin G, Benard A, Damond F, Mouscadet JF, Brun-Vezinet F, Descamps D
Affiliation(s): Hopital Bichat-Claude Bernard, Laboratoire de Virologie, 46 Rue Henri Huchard, 75018 Paris, France. charlotte.charpentier@bch.aphp.fr
Publication date & source: 2011-03, Antimicrob Agents Chemother., 55(3):1293-5. Epub 2010 Dec 28.
Publication type: Research Support, Non-U.S. Gov't
We studied seven heavily pretreated HIV-2-infected patients exhibiting a virological failure while receiving a salvage raltegravir-containing regimen. At the time of virological failure, different resistance genetic pathways were observed: T97A-Y143C, Q148K, Q148R, G140S-Q148R, E92Q-Y143R-N155H, and T97A-N155H. Thus, despite a 40% difference in integrase genes between HIV-1 and HIV-2, the genetic pathways leading to raltegravir resistance are similar.
|